John Orwin has been a member of the board of directors of Travere Therapeutics, Inc. since 2017. Mr. Orwin has cultivated more than 25 years of biopharmaceutical experience during tenures at some of the industry’s leading companies. Currently, Mr. Orwin serves as the president and chief executive officer (CEO) of Atreca, Inc., a biopharmaceutical company focused on developing novel therapeutics based on a deep understanding of the human immune response. Prior to Atreca, Mr. Orwin also served as CEO of Relypsa, and as a director and CEO of Affymax, which was preceded by a tenure as the company’s chief operating officer. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin is currently a member of the board of directors of Array BioPharma Inc. and Seagen Inc. Mr. Orwin holds a master’s degree in business administration from New York University and a bachelor’s degree from Rutgers, The State University of New Jersey.